A clinical stage company developing next-generation therapies to extend healthy lifespan.

Cambrian Biopharma is a clinical stage platform company focused on developing novel medicines that target the causes of aging and age-associated diseases such as cancer, heart disease, and dementia. The company primarily employs a “buy and build” strategy wherein it identifies and acquires a significant or controlling stake in early-stage companies and provides operational support to advance these novel platforms. The first of Cambrian’s subsidiaries, Sensei Biotherapeutics (NASDAQ: SNSE) had a successful IPO in February 2021 and was valued at over $581M on its first day of trading.

‍